PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0851-0031
U.S. Palent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Un	der the Paperwork Reduction a	Act of 18	95, no persons are required to a	aspond to a collection of Infor	mation unless it contains a valid OMB control number	
Sub	satitute for form 1449/PTO			Complete if Known		
				Application Number	10/527,679-Conf. #7223	
11	VFORMATION	I DI	SCLOSURE	Filing Date	March 11, 2005	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Thomas FELZMANN	
				Art Unit	1646	
	(Use as many sh	eets as	necessary)	Examiner Name	X. Xie	
Sheet	1	of	3	Attorney Docket Number	4518-0110PUS1	

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
_					

		FOREIG	ON PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ³ (# Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Linas, Where Relevant Passages Or Ralevant Figures Appear	'n
						-
						E
Examiner Signature		/Xiaozhen Xie/		Date Considered	08/14/2010	

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 000. Draw line through chaston if not in conformance and not considered, include copy of this form with next communication to preferent." Applicants unique obtains designation number (optional). They know to Codes of Applicants and the conformance of the conformal included in the conformance of the conformation of the conformation of the prevent of the preve

PTO/SSIGNE (67-05)

Approved for use through 07/210/210/2 AND 6051-00/21

U.S. Palent all Tiedemark Office, U.S. DEPARTIMENT OF COMMERCE
Under the Paperrook, Reduction Act of 1995, no persons are required to respond to a collection of Information units of a contral available.

Sut	estitute for form 1449/PTO			Complete If Known		
				Application Number	10/527,679-Conf. #7223	
11	VFORMATION	I DI	SCLOSURE	Filing Date	March 11, 2005	
s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Thomas FELZMANN	
_				Art Unit	1646	
	(Use as many sh	eets as	s necessary)	Examiner Name	X. Xie	
Sheet	Sheet 2 of 3		Attorney Docket Number	4518-0110PUS1		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), liftle of the article (when appropriate), little of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(e), volume-issuo number(s), publisher, city and/or country where published.	T²
	CA	CZERNIECKI, Brian J. et al., "Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleutin-12 burst secretion", Cancer Res., February 15, 2007, Vol. 67, No. 4, pp. 1842-1852.	
	СВ	DAVIS, Daniel M., "Mechanisms and functions for the duration of intercellular contacts made by lymphocytes", Nature Reviews Immunology, August 2009, Vol. 9, pp. 543-555	
	cc	DOHNAL, A. M. et al., "Phase i study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer", Cytotherapy, 2007, Vol. 9, No. 8, pp. 755-770.	
	CD	DOHNAL, A. M. et al., "Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines", J. Cell. Mol. Med., 2009, Vol. 13, No. 1, pp. 125-135.	Г
	CE	DOHNAL, A. M. et al., "CD40 ligation restores type 1 polarizing capacity in TLR4-activated dendrific cells that have ceased interleukin-12 expression", J. Cell. Mol. Med., 2009, Vol. 13. No. 8, pp. 1741-1750.	
	CF	FELZMANN, Thomas et al., "Semi-mature iL-12 secreting dendritic cells present exogenous antigen to trigger cytolytic immune responses", Cancer Immunol. Immunother., 2005, Vol. 54, pp. 769-780.	
	cg	Huettner, Katharaina Gabriele et al., "Generation of potent anti-tumor immunity in mice by interleukin-12 secreting dendritic cells", Cancer immunol immunother, 2005, Vo. 54, pp. 67-77.	
	СН	Kalinski, Pawel et al., "Final maturation of dendritic cells is associated with impaired responsiveness to IFN-y and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells", The Journal of Immunology, 1999, Vol. 162, pp. 3231-3238.	
	CI	LANGENKAMP, Anja et al., "Kinetics of dendritic cell activation: Impact on primin of TH1, TH2 and nonpolarized T cells", Nature immunology, October 2000, Voj. 1, No. 4, pp. 311-316.	Г
	CJ	LUO, Jun-Li et al., "IKK/NF-KB signaling: balancing life and death - a new approach to cancer therapy", The Journal of Clinical investigation, October 2005, Vol. 115, No. 10, pp. 2625-2632.	Г

Examiner Signature	/Xiaozhen Xie/	Date Considered	08/14/2010
			-

^{&#}x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached

PTO/SB/08b (07-09)

Approved for use through 07/31/2022, OMB 0681-0031
U.S. Pationt and Trademank Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a coelection of information unless of containts a valid office for information unless of containts a valid office of information unless of containts a valid office of information unless of containts a valid office of information unless of containts and office of information unless of containts a valid office.

Sut	stitute for form 1449/PT	o		Complete If Known		
				Application Number	10/527,679-Conf. #7223	
11	IFORMATIC	ID NC	SCLOSURE	Filing Date	March 11, 2005	
l s	TATEMENT	BY	APPLICANT	First Named Inventor	Thomas FELZMANN	
				Art Unit	1646	
	(Use as many	sheets as	necessary)	Examiner Name	X. Xie	
Sheet	3	of	3	Attorney Docket Number	4518-0110PUS1	

		NON PATENT LITER	ATURE DOCUMENTS						
-	Cite No. ¹	include name of the author (in CAPTAL LETTERS), little of the article (when appropriate), title of the from (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	ск	STEINMAN, Ralph M. et al., "Taking dendritic cells into medicine", Nature, September 27, 2007, Vol. 449, pp. 419-426.							
	CL	SUFFREDINI, Anthony F. et al., "Dose-related inflammatory effects of intrevenous endotoxin in humans: Evaluation of a new clinical lot of <i>Escharichia coli</i> 0:113 endotoxi", The Journal of Infactious Diseases, 1999, Vol. 179, pp. 1278-1282.							
Examiner Signature		/Xiaozhen Xie/	Date Considered	08/14/2010					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.